Among the five histological types, the mutation rates of KRAS were 34.3% in adenocarcinoma, 60.0% in mucinous adenocarcinoma, 0% in low adhesion carcinoma, 50% in signet-ring cell carcinoma, and 50% in squamous cell carcinoma, respectively. This evidence concerns the gene KRAS and adenocarcinoma.